← Leaderboards
Jon G Mabley
Inotek Pharmaceuticals Corporation
$947,474
Attributed
$947,474
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$947,474 · 5
By mechanism
R43$836,126 · 4
R21$111,348 · 1
Top collaborators
No co-investigators on record.
Most similar at Inotek Pharmaceuticals Corporation
Same institution · by research overlap
- Csaba Szabo$15,264,870
- Garry John Southan$13,828,224
- Prakash Jagtap$6,029,479
- Ludmila Belayev$1,038,850
- Kanneganti Murthy$5,565,701
Others in their field
Top investigators on “Peroxynitrites”
- Kenneth D. Karlin · Johns Hopkins University$12,134,278
- Richard A Cohen · Boston Medical Center$9,187,939
- Swapnil K. Sonkusare · University Of Virginia$7,826,642
- Steven S Gross · Weill Medical College Of Cornell Univ$7,254,111
- Andrew L Salzman · Inotek Pharmaceuticals Corporation$7,181,501
- Carl F Nathan · Weill Medical College Of Cornell Univ$6,904,344
Research focus
PeroxynitritesDrug Design /Synthesis /ProductionPentosyltransferaseEnzyme InhibitorsEnzyme ActivityDrug Adverse EffectPharmacokineticsInsulin Dependent Diabetes MellitusPancreatic IsletsDisease /Disorder ModelDrug Screening /EvaluationImmunocytochemistryLaboratory MouseDoxorubicinCatalystDogsHemodynamicsCardiotoxinApoptosisHeart PharmacologyFree RadicalsCytotoxicityFree Radical OxygenFluid
Grant awards (5)
Novel preservation fluid for organ transplantation$183,523
R43 · FY2003 · DK
Peroxynitrite decomposition catalyst: hemorrhagic shock$277,110
R43 · FY2002 · GM
Poly(ADP-ribose)Polymerase &Doxorubicin Cardiotoxicity$250,000
R43 · FY2002 · CA
ORALLY ACTIVE INHIBITOR OF POLY (ADP) RIBOSE SYNTETHASE$125,493
R43 · FY2000 · DK
POLY(ADP) RIBOSE SYNTHETASE AND AUTOIMMUNE DIABETES$111,348
R21 · FY2000 · DK